Bottom line
Is CMCMX a good fund? The bottom line
CMCMX is the Investors Class share class of Conestoga Discovery Fund, a managed large blend mutual fund from Conestoga.
Its expense ratio is 1.5% — about $150 a year on every $10,000 invested, more expensive than 84% of large blend funds we track.
It returned +16.4% over one year, −0.9% a year over five years (as of Dec 31, 2025, per its prospectus).
With $5.7 million in net assets and 29 holdings, its largest position is Twist Bioscience Corp (5.6%) and the top 10 make up 46.7% of the portfolio.
What to watch
- Expensive for its category (1.5%)
- 5-year return in the bottom quarter of its category
- 12b-1 marketing fee of 0.25% a year
- Small fund ($5.7 million) — small funds are likelier to close
Updated Nov 19, 2026
What CMCMX invests in
The Fund seeks to provide long-term growth of capital.
Under normal market circumstances, the Fund invests at least 80% of its net assets in equity securities of micro-capitalization companies. Equity securities include common and preferred stocks, both domestic and foreign, convertible securities, rights, warrants and American depositary receipts (ADRs). While there is no limit on investing in foreign securities, the Fund does not expect investment in foreign securities to exceed 20% of the Funds total assets. The Adviser considers micro market capitalization (micro-cap) companies for this purpose to be those companies that, at the time of initial purchase (including the existing portfolio), have market capitalizations generally within the range of companies included in the Russell Micro Cap Growth Index. The Fund will not change this policy unless it notifies shareholders at least 60 days in advance. This policy does not require the Fund…
From the fund's prospectus (filed Feb 3, 2026).
CMCMX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| CMCMX | +16.4% | −0.9% | — |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What CMCMX costs
On a $10,000 investment, CMCMX's 1.5% expense ratio costs about $150 a year. The prospectus estimates $6,629 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
CMCMX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Twist Bioscience Corp | 5.59% |
| 2 | Mama's Creations Inc | 5.36% |
| 3 | Vericel Corp | 5.04% |
| 4 | Digi International Inc | 5.02% |
| 5 | Transcat Inc | 4.47% |
| 6 | Electrovaya Inc | 4.46% |
| 7 | Graham Corp | 4.28% |
| 8 | Biolife Solutions Inc | 4.23% |
| 9 | Palomar Holdings Inc | 4.20% |
| 10 | Cryoport Inc | 4.06% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 46.7% of the fund. See all top 25 holdings and asset mix →